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Abstract
The current geriatric population in the United States accounts for approximately 12% of the total population and is 
projected to reach nearly 20% (71.5 million people) by 2030[1]. With this expansion of the number of older adults, 
physicians will face the common complaint of rhinitis with increasing frequency. Nasal symptoms pose a significant 
burden on the health of older people and require attention to improve quality of life. Several mechanisms likely 
underlie the pathogenesis of rhinitis in these patients, including inflammatory conditions and the influence of aging 
on nasal physiology, with the potential for interaction between the two. Various treatments have been proposed to 
manage this condition; however, more work is needed to enhance our understanding of the pathophysiology of the 
various forms of geriatric rhinitis and to develop more effective therapies for this important patient population.
Classifications
Rhinitis is defined as inflammation of the nasal mucosa
and is characterized by symptoms of congestion, rhinor-
rhea, itching of the nose, postnasal drip, and sneezing[2].
In the geriatric population, a broad interpretation of this
symptom complex may also include crusting within the
nose, cough, excessive drainage, olfactory loss, and nasal
dryness[3,4].
Rhinitis can be divided broadly into two major catego-
ries: allergic and nonallergic (Appendix 1).
Allergic rhinitis is an IgE-mediated inflammation of the
nasal passageways triggered by various allergens such as
dust, pollens, or molds. Symptoms of allergic rhinitis may
be classified as seasonal or perennial. An international
working group modified this classification scheme due to
potential difficulties in differentiating between seasonal
and perennial symptoms and created the Allergic Rhinitis
and its Impact on Asthma (ARIA) Report[5]. The ARIA
guidelines temporally classify allergic rhinitis as 'intermit-
tent' if symptoms are present less than four days per week
or less than four consecutive weeks, or as 'persistent' if
symptoms are present more than four days per week and
for more than four consecutive weeks. Severity of symp-
toms is graded as 'mild' if they are present but not trou-
blesome, and as 'moderate/severe' if they lead to sleep
disturbance, impairment of daily activities, or impair-
ment of school or work.
Nonallergic rhinitis is characterized by non-IgE-medi-
ated symptoms typical of rhinitis, such as congestion and
clear rhinorrhea, with less prominence of sneezing and
ocular/nasal pruritis[6,7]. The associated symptoms may
be perennial or sporadic, lacking a clear seasonality, and
may be exacerbated by nonspecific triggers such as odors,
food, emotion, or change in atmospheric condi-
tions[5,8,9]. Though no formal classification system
exists, nonallergic rhinitis can be further subcategorized;
most commonly seen in older patients are the vasomotor,
atrophic, gustatory, and medication-induced sub-
types[10,11].
Epidemiology
Allergic rhinitis affects approximately 10-30% of Ameri-
can adults[2,12]. The condition predominantly affects
males in their late teens or young adulthood and the
prevalence decreases with age[12,13]; yet, it is estimated
that three per one thousand individuals over the age of 65
also suffer from allergic rhinitis with a shift to female pre-
dominance after adolescence[13,14]. Cross-sectional and
longitudinal studies have shown that both allergic rhinitis
symptoms and allergic skin test sensitivity become milder
over time; however, these findings may not necessarily
correlate[15,16]. Such changes may be due to alterations
in immune function with age[17,18]. For instance, total
IgE levels and eosinophil degranulation in response to
cytokine stimulation decrease with age[19,20]. Further-
more, repetitive exposure to allergens may induce toler-
ance or anergy over time through mechanisms that are
not completely clear[14].
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There is substantially less research regarding frequency
of nonallergic rhinitis in comparison to allergic rhinitis in
older subjects. An estimated 19 million people in the
United States suffer from nonallergic rhinitis[21]. The
prevalence of nonallergic rhinitis is greater in females and
the incidence of diagnosis increases with age[22-24].
Greater than 60% of rhinitis patients over the age of 50
suffer from a nonallergic etiology[9].
Effects of Rhinitis on Quality of life
Several studies have shown the deleterious effects of rhin-
itis on the quality of life in symptomatic patients. Ben-
ninger et al found that allergic rhinitis can result in
significant sleep disturbance and fatigue using the Rhi-
nosinusitis Disability Index (RSDI), a validated outcomes
tool that assesses how allergic rhinitis affects quality of
life[25]. Complaints of poor sleep are already common
among older individuals due to various sleep disorders as
well as the normal aging process[26], thus allergic rhinitis
may exacerbate these problems. Lack of sleep can alter
physiological processes such as glucose metabolism, cog-
nition, appetite control, and endocrine function, all criti-
cal physiologic processes in older people[27,28].
Longitudinal studies have demonstrated that sleep com-
plaints in the geriatric population are also associated with
lower self-reported health status, depression, and
increased mortality[29-32]. Other effects of allergic rhini-
tis include headache, poor concentration, and general
irritability. These symptoms may hinder an individual's
ability to carry out physical and social responsibilities
effectively[2]. Both of these domains were found to be
large factors that contribute to geriatric quality of
life[33,34].
Little data are available that specifically address the
effects of nonallergic rhinitis on quality of life, especially
in geriatric subjects. Because allergic and nonallergic
rhinitis share similar symptoms, the two conditions are
perceived by patients similarly[35] and it would be plausi-
ble to extrapolate data on allergic rhinitis to model the
effects of nonallergic rhinitis. In fact, a recent study dem-
onstrated a decrease in health-related quality of life in
both allergic and nonallergic rhinitis patients; indeed,
there was no significant difference in the degree of
impairment between the two patient populations[36].
Physiological Changes with age that may affect 
Rhinitis
Immunosenescence
Rhinitis is an inflammatory disease, as such, mechanisms
and presentation of the condition are altered as immune
function changes with age, a concept entitled immunose-
nescence. A critical component of the immune system is
the thymus, which rapidly involutes from adolescence to
near middle age, followed by an approximate 1% loss per
year thereafter[37]. The decline in functional mass causes
depressed production of naïve T-cells leading to impaired
cell-mediated immunity[37,38]. Despite thymic involu-
tion, the total T-cell pool remains constant due to an
increase in production of memory T-cells[38]. The cause
of this heterogeneity in the lymphocyte pool remains
unknown. With the aging process also comes decreased
T-cell responsiveness to growth factors, altered lympho-
cyte response to specific antigens, and diminished IL-2
production and receptor expression[17]. An imbalance in
the Th1/Th2 ratio occurs during immunosenescence,
with a shift towards Th2, leading to further altered
cytokine production[39]. This is somewhat of a paradox
since the incidence of allergic rhinitis declines with age.
The diminished T-cell response may be associated with
the increased incidence of malignancy and infections in
the geriatric population[17,40], whereas the aberration in
cytokine production and inflammatory response may
explain chronic or late onset rhinitis.
B-cell function changes with age as well. Although the
peripheral B-cell population remains consistent, there is
less IgG isotype class switching, and the number of anti-
gen-specific antibodies decreases while the number of
autoantibodies and circulating immune complexes
increase[17,18]. This may explain the fact that older indi-
viduals are prone to infection, have decreased immune
response to vaccines, and have increased prevalence of
autoimmune diseases[17,38,40]. These changes might
a lso c on t ri but e  t o  t he  m il der  sym pt om s  as  we l l as  t he
decreased incidence of allergic rhinitis in the geriatric
population.
Changes of the Aging Nose
Structural
As individuals age, several changes in nasal anatomy and
physiology occur which may affect the development and
expression of rhinitis. A loss of nasal tip support develops
because of weakening of fibrous connective tissue at the
upper and lower lateral cartilages[4]. Collagen and elastin
loss, maxillary alveolar hypoplasia, and decreased facial
musculature lead to a drooped tip[41]. Furthermore,
weakening and fragmentation of septal cartilage and
retraction of the nasal columella leads to changes in the
nasal cavity[42]. A combination of these structural
changes may decrease nasal airflow leading to complaints
of nasal obstruction commonly seen in geriatric rhinitis
patients.
Mucus
Mucosal epithelium atrophies with age and older patients
are frequently dehydrated[43,44]. These factors may
account for the excessively thick mucus in older patients.
Thickened mucus along with decreased mucociliary
clearance (see below) is thought to lead to common rhi-
nitic complaints such as postnasal drip, cough, and glo-Pinto and Jeswani Allergy, Asthma & Clinical Immunology 2010, 6:10
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bus. Edelstein was able to demonstrate that the
prevalence of postnasal drip, nasal drainage, coughing,
and sneezing increased with age[4].
Nasal Humidification and Dryness
It is well recognized clinically that older people are more
susceptible to dryness in the nose. Lindemann et al illus-
trated that temperature and humidity values in the nasal
cavities were significantly lower in geriatric patients when
compared to younger individuals[45]. Other reasons for
decreased humidification include age-related changes in
nasal vasculature. For instance, submucosal vessels
become less patent and therefore are not able to moisten
and warm inspired air in the older nose as compared to
the younger nose[44]. These findings in geriatric patients
likely explain the typical symptoms of nasal irritation
related to dryness and crusting.
Nasal Airflow
The effects of age on nasal airflow still remain largely
unclear. Calhoun et al did not find a relationship between
age and nasal resistance[46], whereas Vig and Zajac
determined that there is a direct relationship between age
and both nasal resistance and breathing mode[47]. Edel-
stein found a significant correlation between aging and
nasal airway resistance, before and after decongestant
use[4]. Kalmovich et al studied endonasal architecture in
geriatric patients using acoustic rhinometry and con-
cluded that endonasal volumes and minimal cross-sec-
tional areas gradually increase with age[48]. The reason
for the discrepancy between the latter two studies is
unclear. Sahin-Yilmaz and Corey suggest this difference
may be due to decreased functioning of the nasal
mucosa[10]. The authors note that the estrogen content
in the nasal mucosa decreases with age and can subse-
quently cause to loss of softness and elasticity, leading to
increased airway resistance. Post-menopausal women
may also suffer from olfactory loss, nasal congestion, and
an increase in mucociliary time secondary to hormonal
changes[49]. Estrogens modulate mucosal function by
modifying the local concentration of neurotransmitters
or their receptors, which regulate basal vasculature and
glandular secretions[49]. Recent evidence suggests that
the number of specific estrogen receptors (ERβ) within
the nasal mucosa positively correlates to rhinitic symp-
toms, yet the mechanism of the receptors' effects on nasal
m u c o s a  i s  y e t  t o  b e  e l u c i d a t e d [ 5 0 ] .  I t  i s  p l a u s i b l e  t h a t
other airflow abnormalities could also underlie nasal
complaints in older subjects.
Mucociliary Clearance
Studies show that the frequency at which cilia beat, as
well as time for mucociliary clearance within nasal epi-
thelium, slow with age[51]; however, the number of cili-
ated cells in the nasal epithelium does not change[4]. In
fact, Kirtsreesakul et al have recently shown that the
severity of symptoms was significantly correlated with
the mucociliary transport time in patients classified with
moderate-severe allergic rhinitis[52]. This may be due to
poor clearance of allergen and irritants, as well as stasis of
thick, dehydrated mucus within the nasal cavities and
nasopharynx, leading to rhinitis complaints among the
geriatric population of postnasal drip, cough, and globus.
Olfaction
Olfactory function decreases with age, with more rapid
decline after the seventh decade. Both the sense of smell
(detection) and the ability to discriminate between two
scents is decreased with the normal aging process[53].
Olfactory dysfunction is also commonly associated with
rhinitis. One study demonstrated that 71% of study sub-
jects complaining of dysosmia had positive allergy skin
tests[54]. The mechanism for olfactory dysfunction in
allergic rhinitis patients has been typically attributed to
nasal obstruction; however, newer data suggest that the
etiology may be due to inflammation in the olfactory cleft
itself[55]. This inflammation may be responsive to intra-
nasal steroids. Of note, one trial has demonstrated that
the sense of smell in nonallergic rhinitis patients was
worse than in allergic rhinitis patients[56]. Together, this
data illustrates that though olfactory dysfunction may be
primarily due to the aging process, rhinitis may present as
a 'second hit' that aggravates the problem.
Pathophysiology and Clinical Presentation of 
Rhinitis
Allergic
T o briefly review, allergic rhinitis is the result of type I
hypersensitivity reactions whereby exposure to allergens
in susceptible individuals leads to sensitization by pro-
duction of specific IgE antibodies directed against these
extrinsic proteins. This antibody then binds to the surface
of mast cells, and when the allergen is reintroduced, IgE
cross-binding to the antigen leads to mast cell degranula-
tion[57]. Within seconds of contact, inflammatory medi-
ators such as histamine, leukotrienes, and prostaglandin
D2 are released causing vascular endothelial dilation,
which subsequently causes leakage and mucosal
edema[58,59]. This leads to nasal obstruction and symp-
toms of congestion, redness, tearing, swelling, ear pres-
sure, and postnasal drip. Irritant receptors are stimulated
by the allergen causing itching and sneezing[60].
Within four to eight hours of initial exposure, cytokines
attracted by previously released mediators lead to
recruitment of other inflammatory cells to the mucosa,
such as neutrophils, eosinophils, lymphocytes, and mac-
rophages[59]. The inflammation persists and this stage is
termed the late-phase response. The late-phase response
presents similar to the early phase, however, sneezing and
itching are less prominent, whereas congestion and
mucus production are more severe. The late phase may
persist for hours or days[61].Pinto and Jeswani Allergy, Asthma & Clinical Immunology 2010, 6:10
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Though its peak incidence is during young adulthood,
allergic rhinitis is prevalent among older people. In fact,
the 2005 National Center for Health Statistics report
stated that 10.7% of individuals between 45-64 years of
age, 7.8% of patients 65-75 years of age, and 5.4% of
patients older than 75 are affected by allergic rhinitis[62].
Along with the anatomic and physiologic changes of the
nose, non-specific immune changes such as decreased
mucus production and ineffective cough mechanisms are
all thought to contribute to persistent or late-onset aller-
gic disease in older people, as these processes are neces-
sary for clearance of allergens and irritants[17].
Interestingly, Jackola et al. illustrated that atopic individu-
als with a positive family history did not have a change in
severity or sensitivity of a t opy as t hey age. Also, t here
were no changes in the amount of IgE specific to ragweed
extract, despite age-related decline of total serum IgE[63].
Mediaty et al also demonstrated that immunosenescence
does not affect increased IgE levels in atopic patients with
atopic dermatitis or high serum IgE levels[64]. In sum-
mary, these findings suggest that the atopic predisposi-
tion remains present into advanced age in these
subgroups of patients. Therefore, allergic rhinitis should
not be overlooked in the geriatric population if a patient's
history and symptoms are consistent with this condition.
Nonallergic
Vasomotor
Vasomotor rhinitis is the most common form of nonaller-
gic rhinitis, and its prevalence is increased in the aging
population[22]; however, due to the difficulties in classi-
fying this condition, epidemiological data is scant. This
condition does not have an obvious immunologic or
infectious etiology and is not associated with nasal
eosinophilia[2]. Prominent symptoms of vasomotor rhin-
itis include nasal obstruction, rhinorrhea, and conges-
tion[6,65]. These symptoms are exacerbated by strong
odors or fumes, bright lights, and changes in weather or
humidity[65,66].
The mechanism of vasomotor rhinitis is unclear. One
theory is that autonomic instability may lead to both
hyperactive parasympathetic activity and an imbalance in
sympathetic to parasympathetic activity in vasomotor
patients, which cause nasal congestion and rhinor-
rhea[67]. The sympathetic pathway promotes nasal air-
way patency by secretion of norepinephrine and
neuropeptide Y[68], whereas the parasympathetic path-
way releases substances that lead to congestion and
mucus secretion such as acetylcholine. Thus, vasomotor
rhinitis in older patients may represent a decline in con-
trol of neurological responses that affect nasal physiology.
Another possibility may be that neurogenic reflex
mechanisms triggered by environmental factors (e.g.,
ozone, cigarette smoke) lead to inflammatory responses
in the nose. Sensory nerves of the nasal mucosa respond
to chemical stimuli by initiating sneezing and nasal
hypersecretion through reflex pathways. The sensory
fibers that are unmyelinated and slow conducting belong
to the C-fiber type and contain neuropeptides such as
substance P, calcitonin gene-related peptide, and vasoac-
tive intestinal peptide, which regulate glandular secre-
tions and vascular tone[67,69]. Baraniuk and colleagues
have demonstrated that these neuropeptides communi-
c a t e  w i t h  i m m u n e  m e d i a t o r s ,  s u c h  a s  h i s t a m i n e .  T h e
interplay between these molecules may cause neural
responses and vice versa, all leading to an integrated
response to external stimuli[70]. These mechanisms may
be involved in the etiology of vasomotor rhinitis in older
people.
Cardell et al recently studied nasal mucosa biopsies of
nonallergic rhinitis patients using microarray analy-
sis[71]. The group noted at least ten genes to be involved
in nonallergic rhinitis, relating to functions of cellular
movement, hematological system development, and
immune response. Two of these genes, c-fos and cell divi-
sion cycle 42 (cdc42) were found to have pivotal roles in
the possible mechanistic pathways of nonallergic rhinitis
and the authors believe these genes could be potentially
useful as biomarkers for this condition and aid in diagno-
sis. These data are preliminary and will require follow-up.
Gustatory
Gustatory rhinorrhea is characterized by profuse watery
rhinorrhea following ingestion of certain foods. These
symptoms can be socially awkward and even lead to
decreased nutrition. Commonly, alcohol and spicy or
cold foods are the culprits. With spicy food, the capsaicin
content induces neuropeptide release from sensory nerve
fibers, leading to overstimulation of the parasympathetic
nervous system[67]. Baraniuk and colleagues demon-
strated the significance of the TRP (transient receptor
potential) receptor family in the regulation of sensory
neuron depolarization and repolarization, glandular exo-
cytosis, and many other functions. Substrates for these
receptors include capsaicin, extremely high or low tem-
peratures, alcohol, mustard oil, and some garlic compo-
nents[72]. One speculation is that TRP receptors may
play a role in gustatory rhinorrhea.
Medication-induced
Several classes of medications are known to induce rhini-
tis (Appendix 2). The mechanisms causing this include
alteration of autonomic regulation on nasal mucosa and
vasculature, platelet activity, immune effects, and hor-
monal effects. This condition is of particular importance
in older patients, as polypharmacy has become a com-
mon issue among the geriatric population with an
increasing amount of comorbid conditions. Although the
number of individuals over 65 years of age represents less
than 15% of the total population, this group accounts forPinto and Jeswani Allergy, Asthma & Clinical Immunology 2010, 6:10
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over one third of prescription drug use nationwide[73].
Furthermore, Kaufman et al discovered that 57% of
American women greater than 65 years of age use at least
five medications and 12% use at least ten medica-
tions[74]. Common agents used in the geriatric popula-
tion that can induce rhinitis are discussed below.
Medications with effects on the cardiovascular system
carry side effects of rhinitis due to disruption of the nor-
mal sympathetic tone that causes vasoconstriction of
local vessels. Medications such as alpha and beta-block-
ers, centrally acting anti-hypertensives, and angiotensin
converting enzyme (ACE) inhibitors that inhibit sympa-
thetic tone lead to vasodilation and symptoms of nasal
congestion. Antipsychotics also have well-known rhino-
logic side effects due to their alpha and beta blocking
properties[75].
Topical decongestants can cause rebound vasodilation
with overuse. The older population is at increased risk for
this adverse effect due to thinning and dryness of their
nasal mucosa[76].
Aspirin-sensitive patients may suffer from rhinitis with
use as well as prolonged epistaxis due to its anti-platelet
activity. Other systemic medications that cause rhinitis
are contraceptives, erectile dysfunction therapies, immu-
nosuppressants, antivirals, penicillamine, and oral retin-
oids[75].
Primary atrophic
Geriatric rhinitis, or primary atrophic rhinitis, is an
imprecise term used to signify rhinitis due to the age-
related changes in nasal physiology (nasal glandular atro-
phy, vascular changes, decreased nasal humidification,
decreased mucociliary clearance, and structural changes
of the nose)[77]. Histopathological changes associated
with primary atrophic rhinitis include mucosal atrophy,
squamous metaplasia, and chronic inflammatory cell
infiltrate[78]. Garcia et al studied how these changes lead
to symptoms using techniques of computational fluid
dynamics of airflow and water and heat transport, finding
that excessive evaporation of the mucus layer secondary
to widened nasal cavities and decreased mucosal surface
area are integral components of atrophic rhinitis[79].
These changes lead to thickened and persistent mucus
and altered nasal airflow. Recent studies have attempted
to elucidate the role of apoptosis in rhinitis, finding that
nasal epithelium from patients suffering from atrophic
rhinitis display increased activity of caspase 3, a key pro-
tein in the apoptosis cascade[80]. This finding directs
future studies to investigate therapeutic strategies that
may regulate apoptosis.
Patients suffering from primary atrophic rhinitis, a
diagnosis of exclusion, typically present with symptoms
of postnasal drip, chronic cough, and nasal obstruction
and dryness. Patients may also complain of a frequent
need to clear the throat, thick and dense secretions, as
well as bothersome nasal crusting upon awaken-
ing[77,78,81]. Because this progressive condition pres-
ents with symptoms similar to other types of rhinitis, it is
often improperly diagnosed and undertreated. More
work needs to be done to recognize atrophic rhinitis as
well as to administer effective treatment.
For completeness, we mention that secondary atrophic
rhinitis is seen in patients with extensive nasal surgery,
trauma, granulomatous diseases, and radiation ther-
apy[82] and will not be discussed here.
Evaluation
Diagnosis and treatment of rhinitis in the older popula-
tion is complicated by comorbid conditions. Approxi-
mately 50% of people over the age of 75 have three or
more diseases and take three or more medications[83].
Within this population, there are also concerns of compli-
ance due to physical or cognitive impairments and finan-
cial issues[83]. Furthermore, many older patients with
rhinitis complain of "sinus trouble" or "allergies", thus it is
difficult to assess the specific type of rhinitis involved or
the appropriate treatment[77].
Evaluation of an older patient with rhinitis should begin
with a complete history. Details regarding length and
timing of symptoms, exacerbating factors, and response
to medications should be elicited from the patient. Also
important for investigation are environmental exposures
such as tobacco smoke, pets, pollution, housing type
which may be older and might contain formaldehyde for
insulation or upholstery finishing, cockroaches and
rodents. Activities requiring use of latex gloves, certain
cleaning products, certain glues, wood dust, and acid
anhydrides can trigger symptoms of rhinitis[84]. Interest-
ingly, psyllium powder from Metamucil preparation
(commonly used in the older patient for constipation) has
been reported to induce acute rhinitis[85].
Past medical history consisting of trauma to the nose or
face, asymmetry of nasal breathing due to structural
causes, allergic conditions such as asthma and eczema, as
well as family history of atopy should be noted. Though
the typical age of onset of allergic rhinitis is under age 20
years, humans can be sensitized at any time [14], there-
f o r e  a n  a l l e r g i c  c a u s e  s h o u l d  n o t  b e  p e r f u n c t o r i l y  d i s -
missed.
Physical examination should begin with externally
inspecting the tip of the nose for drooping and absence of
structural support. Internally, the physician should assess
nasal patency, turbinates, straightness of the septum,
presence of polyps, and signs of inflammation. Most of
this endonasal examination can be accomplished with an
otoscope. Mucosal evaluation may be challenging to
interpret as both allergic and nonallergic rhinitis can
present with mucosal pallor, edema, or hyperemia[2].
Overuse of topical medications may cause the nasalPinto and Jeswani Allergy, Asthma & Clinical Immunology 2010, 6:10
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mucosa to appear reddened. The quality of secretions
may aid in distinguishing the etiology of rhinitis. For
instance, allergic rhinitis typically presents as watery
mucus, whereas in mucociliary defects or severe obstruc-
tion, thick mucus can be seen pooling on the nasal
floor[2]. Furthermore, mucopurulent drainage along with
"cobblestoning" of the pharynx may be suggestive of
chronic rhinitis complicated by acute sinusitis. In most
cases of rhinitis, findings should be bilateral. Unilateral
findings may reflect anatomic pathology or neoplasm
requiring further workup including nasal endoscopy or
sinonasal imaging by computed tomography (CT) scan.
The remainder of the physical examination should be
employed to eliminate other causes of rhinitis including
cerebrospinal fluid rhinorrhea and tumors.
Allergy testing is useful both to determine atopy status
with total serum IgE (usually > 100 U/mL)[86] as well as
to identify the specific offending allergens (specific IgE).
It should be noted, however, that response to skin testing
decreases with age and photo damage, requiring skin
tests in geriatric patients to be interpreted with care[87].
Other factors that may affect a skin test in the geriatric
population are medications (most notably long-acting
antihistamines and tricyclic antidepressants), blood pres-
sure, temperature of the extremity, and change in the
allergen exposure over time[87]. When administering a
skin test to an older individual, a sun-protected area of
the skin should be used for testing, such as the lower
back. If an acceptable area cannot be found, the physician
should consider in vitro testing.
By definition, patients with nonallergic rhinitis demon-
strate negative test results. Nonallergic rhinitis is a diag-
nosis of exclusion due to the absence of specific
laboratory tests that confirm this diagnosis[67].
Adjunct testing can also be useful in the evaluation of
rhinitis in older subjects. Upper airway endoscopy is
valuable in identifying any anatomic abnormalities that
may not have been visualized on anterior rhinoscopy,
such as septal deviation, nasal polyposis, or mucosal atro-
phy. Moreover, the middle meatal sinus ostia can be
assessed for signs of obstruction which could predispose
to sinusitis[84,88]. Sinus imaging by screening CT scan
provides information on any obstruction of the
osteomeatal complex, and can also aid in identifying pol-
yps, turbinate edema, or bony abnormalities such as con-
cha bullosae[84]. However, given cost and radiation
exposure, imaging is reserved for cases of lack of
response to therapy, high index of clinical suspicion, or
pre-operative assessment for use during endoscopic sinus
surgery to delineate anatomy[89,90]. Additional special-
ized testing (e.g. acid reflux testing by pH probe, assess-
ment of nasal volume by acoustic rhinometry) can be
useful for evaluation of exacerbating factors, such as gas-
troesophageal reflux disease or decreased nasal patency
in select settings[23,91,92].
Management
General measures
There are a variety of methods to treat rhinitis in older
subjects. In the case of both allergic and nonallergic rhin-
itis, the simplest therapy is eliminating exposure to
known allergens and/or irritants. It should be noted that
some avoidance measures (mite dust covers, air purifiers,
carpet removal) have not been shown to be effective in
reducing symptoms and pose barriers for some patients
regarding cost. Humidification with saline nasal irriga-
tion has been demonstrated to be a safe and effective
technique to reduce nasal dryness and help with the
clearing of thick, tenacious mucus[93,94]. Mucolytic
agents may also help clear thick mucus and provide
symptom relief. Emollients have been shown to help with
nasal crusting[10]. For example, Johnsen et al demon-
strated that in patients suffering from nasal dryness due
to low humidity, use of sesame oil significantly improved
mucosal dryness, nasal stuffiness, and nasal crusting
w h e n  c o m p a r e d  t o  a n  i s o t o n i c  s o d i u m  c h l o r i d e  s o l u -
tion[95]. The measures are generally safe and can be used
adjunctively with other treatments.
Allergic Rhinitis
Treatment of allergic rhinitis has three main components:
avoidance of exposure to known allergens, pharmaco-
therapy, and immunotherapy.
Allergen avoidance
Some forms of allergen avoidance can be effective in
management of allergic rhinitis; though proof in random-
ized trials has been difficult to generate, this is still a stan-
dard recommendation for patients. Staying indoors with
the windows closed while pollens and molds are in their
seasonal and daytime peaks can decrease disease burden.
Other measures include regular vacuuming of carpet,
removal of pets from home, and frequent washing of bed-
ding. These factors are particularly relevant for the older
patient since s/he may spend significantly more time
indoors and therefore may be exposed to allergens such
as dust mites and indoor molds more than outdoor aller-
gens such as pollens. As such, they may face a perennial
allergen challenge which is sometimes more difficult to
control. Cost and practicality must govern recommenda-
tions in this area for costly and difficult measures (e.g.,
carpet removal, HEPA filters, etc.) given the lack of evi-
dence for efficacy for these measures.
Pharmacotherapy
Second generation antihistamines are standard in the
treatment of mild allergic diseases. These agents are
effective in reducing symptoms of nasal and ocular pruri-
tis, rhinorrhea, and sneezing, but do little in managingPinto and Jeswani Allergy, Asthma & Clinical Immunology 2010, 6:10
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nasal congestion[2,96]. Second generation agents are safe
in older rhinitis patients since they do not carry the risk
of anticholinergic or alpha-adrenergic activity[57,76].
First-generation antihistamines should not be prescribed
as they have numerous potential adverse effects on the
central nervous system and interactions with other medi-
cations, which are more pronounced in the geriatric pop-
ulation[10,57,76]. For example, these medications can
affect driving performance more than alcohol, perturb
the normal sleep cycle, and markedly affect attention and
cognitive performance[97,98], all of these factors being
germane to the older patient.
Topical antihistamines, such azelastine, are good alter-
natives to the oral therapy and are approved for seasonal
allergic rhinitis in the United States. Studies have proven
equal efficacy to ebastine, cetirizine, loratadine, and ter-
fenadine in terms of symptom reduction and may also
improve nasal congestion more so than oral antihista-
mines[99]. Azelastine has been shown to be well tolerated
in geriatric patients[100]. Typical adverse events include
bitter taste, sedation, headache, and application site irri-
tation[99,101]. Topical antihistamines have demonstrated
greater efficacy when combined with intranasal steroids
than either agent alone[102]. A new formulation of
azelastine was developed to reduce the bitter taste associ-
ated with the medication. This new product is as effective
as the older version with similar frequency and constella-
tion of side effects[103,104].
Intranasal steroids have become first-line treatment for
moderate to severe allergic rhinitis and effectively treat all
symptoms of rhinitis[105]. A recent randomized con-
trolled trial studied the effects of mometasone furoate
nasal spray in patients older than 65 years of age suffering
from perennial allergic rhinitis, showing it to be an effec-
tive treatment in this cohort[106]. Intranasal steroids are
generally well tolerated by older patients[10,107]; how-
ever, they can aggravate nasal dryness, epistaxis, and
mucosal crusting in geriatric patients[108]. Therefore,
careful instruction in use with patients is critical along
with close follow-up to examine the presence of these
problems in the nose.
Topical and systemic decongestants are alpha-adrener-
gic agonists that significantly reduce nasal congestion,
however they do not relieve symptoms sneezing, pruritis,
and secretions[109]. Decongestants can be used with
antihistamines if a patient presents with multiple rhinitis
symptoms including congestion. Oral agents are avoided
in those older patients with multiple comorbid conditions
such as coronary artery disease, diabetes, hypertension,
hyperthyroidism, narrow angle glaucoma, and symptoms
of bladder neck obstruction[96,110,111]. Side effects
from oral decongestants include palpitations, insomnia,
nervousness, and irritability. Some patients may have
trouble with urination and a decreased appetite[2]. The
major side effect of topical decongestant overuse is
rebound vasodilation and nasal dryness, as well as the
potential for rhinitis medicamentosa with prolonged
use[105,112].
Leukotriene receptor antagonists (e.g. montelukast,
zileuton) decrease the inflammatory response in allergic
rhinitis and limit symptoms of congestion, sneezing, and
rhinorrhea[113]. These agents are weak as a monother-
apy and are commonly used as an adjunct to antihista-
mine or intranasal steroid treatment[96,114]. Long-term
data has not been reported to determine safety of leukot-
riene inhibitors in the older patients, yet these medica-
tions seem to be well tolerated in this population[10,115].
These agents primarily help with congestion and are par-
ticularly useful in asthmatics where they may have the
double benefit of improving lower airway disease.
Intranasal cromolyn sodium can be effective in mini-
mizing allergic rhinitis symptoms in refractory patients.
This agent inhibits the degranulation of sensitized mast
cells thereby preventing the release of mediators of the
allergic response and inflammation[116]. Patients who
are given nasal cromolyn sodium must be instructed to
use it before an anticipated allergen exposure and to use
it on a regular basis during the period of exposure[2].
Cromolyn may require two to three weeks of use before
any benefit is experienced and should be used three to
four times per day[105]. The medication is generally well
tolerated and side effects are minimal[116]. Cromolyn
can be good option in older patients that cannot tolerate
antihistamines and decongestants, or with use of multiple
medications due to its lack of drug interactions [102,116].
Immunotherapy
Immunotherapy is typically regarded as a last line therapy
when patients continue to have moderate to severe aller-
gic rhinitis symptoms despite pharmacologic interven-
tion. Few studies have been conducted on the efficacy of
immunotherapy in the geriatric population; however, the
data thus far seems positive. Eidelman et al reported a
favorable response to specific immunotherapy in patients
greater than 60 years of age compared to controls aged
less than 60[117]. Asero conducted a study assessing
patients older than 54 years of age with monosensitiza-
tion to birch pollen and ragweed[118]. The trial showed
immunotherapy to be an effective treatment in healthy
older individuals with short disease duration (<10 years)
whose symptoms cannot be adequately controlled by
drug therapy alone. Further studies need to be performed
to address the safety profile of this treatment within the
geriatric population.
Nonallergic rhinitis
Vasomotor rhinitis
Pharmacotherapy Azelastine has been approved by the
Food and Drug Administration (FDA) for treatment ofPinto and Jeswani Allergy, Asthma & Clinical Immunology 2010, 6:10
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vasomotor rhinitis. This agent has demonstrated anti-
inflammatory effects and thus can be given for nearly all
symptoms of vasomotor rhinitis including rhinorrhea,
sneezing, postnasal drip, and congestion[119,120]. Intra-
nasal steroids may be given for complaints of nasal
obstruction or congestion[121]; however, a recent study
has shown that steroid use for symptoms of vasomotor
rhinitis triggered by temperature or weather may not be
effective[122]. The use of anticholinergics in this condi-
tion is mainly for symptoms of rhinorrhea[6,123] but the
applicability of this agent to geriatric patients has not
been examined. Sneezing and congestion associated with
vasomotor rhinitis may be relieved with cromolyn
sodium, but is not as effective as a first-line treatment for
these symptoms[6]. There is no evidence for use of topi-
cal or oral decongestants. Empiric use of decongestants is
possible provided that the geriatric patient has no con-
traindications. In summary, pharmacotherapy for vaso-
motor rhinitis is symptom based, thus if one medication
fails current practice is therapeutic trials with other listed
agents.
Novel therapies for VMR A Chinese group demon-
strated polysaccharide nucleic acid fraction of the Bacil-
lus Calmette-Guérin vaccine (BCG-PSN) to be a safe and
effective treatment of vasomotor rhinitis with no
reported adverse events[124]. This therapy requires mul-
tiple injections, which may be difficult and painful of
older patients, and may also require adjunctive treatment
with a topical antihistamine. Follow up for this trial was
only six months and therefore more evidence is necessary
for long-term efficacy and safety of BCG-PSN. Further
study of these findings is needed before this can reach
clinical practice.
Gustatory Rhinorrhea
Atropine decreases the parasympathetic response and
thus is useful in treatment of gustatory rhinorrhea[67].
Intranasal anticholinergic agents, such as intranasal iprat-
ropium, are FDA approved for use in rhinorrhea in aller-
gic and nonallergic perennial rhinitis and are thus very
effective for gustatory rhinorrhea if used before eat-
ing[125]. These medications have few local side effects
such as epistaxis and nasal dryness[105].
Botulinum toxin is a newer therapy for gustatory rhin-
orrhea, however optimal site of administration, optimal
dose, long-term efficacy, and side effects have yet to be
determined[126,127].
Atrophic Rhinitis
The focus of treatment in atrophic rhinitis is to increase
moisture content in the nose. This can be done with gen-
tle hydration, nasal irrigation, improving mucus function
with agents such as guaifenesin, or use of home humidifi-
ers[108]. Over-the-counter mucolytic agents such as
Alkalol can also provide some therapeutic benefit[128].
Surgery
Surgical treatment is also an option in the geriatric popu-
lation. First, structural causes can be addressed. Nasal
reconstruction can be performed to reverse the aging
effects on the nose, such as raising the nasal tip and sup-
porting the lateral cartilage[10]. This should aid in air
flow and nasal function. Similarly, septoplasty with or
without inferior turbinate reduction has been shown to
be beneficial in patients 65 years of age and older[129].
Moreover, functional endoscopic sinus surgery can be
used to address concomitant sinus disease. Sinus surgery
has been shown to be a safe and efficacious procedure in
older patients[130,131] with improvement in quality of
life. Reh et al demonstrated that older individuals with
chronic rhinosinusitis had a similar degree of improve-
m e n t  i n  e n d o s c o p i c  a n d  q u a l i t y  o f  l i f e  m e a s u r e s  a f t e r
endoscopic sinus surgery when compared to matched
younger controls[132]. Surgery could be an effective
treatment for an older individual, but the functional sta-
tus of the geriatric patient must be assessed pre-opera-
tively to determine if surgery is a suitable option.
Conclusions
Rhinitis is clearly an important burden in the older com-
munity that needs to be further addressed as the geriatric
population rapidly expands in the United States. The
structure and function of the aging nose may contribute
to the manifestations and mechanisms of this condition.
This broad set of symptoms fall under a heterogeneous
group of disorders, and thus the focus of therapy must
first be classification of the patient within the proper sub-
type, and then engagement of appropriate therapy that is
both safe and efficacious in older individuals. Treatment
is challenging as little data exists on clearly beneficial
treatments for several of these subtypes. Trial and error
may prove to be useful in instances where no validated
data are available for geriatric patients. Furthermore, use
of adjunct measures such as allergen/irritant avoidance
and nasal humidification are not only cost-effective, but
can also limit the extent of polypharmacy in a population
with multiple comorbid conditions. More research is
needed to develop effective treatment protocols for this
group of rhinitis patients.
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Appendix 1 - Types of Rhinitis
Allergic
Seasonal
Perennial
Intermittent
Persistent
Nonallergic
Idiopathic/Vasomotor
Nonallergic rhinitis with eosinophilia syndrome
(NARES)
Atrophic
Infectious
Drug-induced
Gustatory
Hormonal
Occupational
Granulomatous
Autoimmune
Appendix 2 - Drug-Induced Rhinitis
Cardiovascular
Beta blockers
Alpha blockers
Centrally acting antihypertensives (methyldopa,
reserpine)
Angiotensin converting enzyme inhibitors
Niacin
Central Nervous System
Typical/atypical antipsychotics
Chlormethiazole
Citalopram
Gabapentin
Endocrine
Oral contraceptives
Estrogens
Sildenafil
Other
Aspirin/NSAIDs
Mycophenolate mofetil
Penicillamine
Lamivudine
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